Reconstitution of beta -Adrenergic Modulation of Large Conductance, Calcium-activated Potassium (Maxi-K) Channels in Xenopus Oocytes
IDENTIFICATION OF THE cAMP-DEPENDENT PROTEIN KINASE PHOSPHORYLATION SITE*

Masayuki Nara, Prasad D. K. Dhulipala, Yong-Xiao Wang, and Michael I. KotlikoffDagger

From the Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6046

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The human large conductance, calcium-activated potassium (maxi-K) channel (alpha  and beta  subunits) and beta 2-adrenergic receptor genes were coexpressed in Xenopus oocytes in order to study the mechanism of beta -adrenergic modulation of channel function. Isoproterenol and forskolin increased maxi-K potassium channel currents in voltage-clamped oocytes expressing the receptor and both channel subunits by 33 ± 5% and 35 ± 8%, respectively, without affecting current activation or inactivation. The percentage of stimulation by isoproterenol and forskolin was not different in oocytes coexpressing the alpha and beta  subunits versus those expressing the only the alpha  subunit, suggesting that the alpha  subunit is the target for regulation. The stimulatory effect of isoproterenol was almost completely blocked by intracellular injection of the cyclic AMP dependent protein kinase (cAMP-PK) regulatory subunit, whereas injection of a cyclic GMP dependent protein kinase inhibitory peptide had little effect, indicating that cellular coupling of beta 2-adrenergic receptors to maxi-K channels involves endogenous cAMP-PK. Mutation of one of several potential consensus cAMP-PK phosphorylation sites (serine 869) on the alpha  subunit almost completely inhibited beta -adrenergic receptor/channel stimulatory coupling, whereas forskolin still stimulated currents moderately (16 ± 4%). These data demonstrate that physiological coupling between beta 2 receptors and maxi-K channels occurs by the cAMP-PK mediated phosphorylation of serine 869 on the alpha  subunit on the channel.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Hormones and neurotransmitters alter cellular excitability in part through the modulation of plasmalemmal ion channel function. Two prominent mechanisms by which hormone/neurotransmitter receptor occupation results in the modulation of membrane ion channels are the phosphorylation of one or more residues of the target channel protein(s) (for review see Ref. 1), and the binding of a heterotrimeric G protein subunit to a modulatory channel domain (for review see Ref. 2). Stimulation of beta 2 receptors relaxes smooth muscle by modulating the activity of several protein targets (3). One prominent target of beta 2 adrenergic signaling in smooth muscle is the large conductance, calcium-activated potassium (maxi-K)1 channel, the activity of which is markedly increased following receptor binding (4-7). Modulation of maxi-K channel activity appears to be a functionally important component of beta -adrenergic relaxation of smooth muscle, since charybdotoxin and iberiotoxin, selective peptide inhibitors of maxi-K channels, markedly inhibit the relaxant ability of isoproterenol and other beta -adrenergic agents (8-10). The molecular mechanism by which channel modulation occurs is unclear, however, since studies have indicated that single maxi-K channels are regulated by phosphorylation and by phosphorylation-independent G protein interactions (5, 6, 11-14). Further, with respect to channel phosphorylation, maxi-K channel stimulation has been attributed to channel phosphorylation by cAMP-dependent protein kinase (5, 6, 11, 15, 16), by cGMP-dependent protein kinase (17-21), and by channel dephosphorylation (19, 22, 23).

Maxi-K channels are composed of at least two dissimilar subunits: the alpha  subunit, which forms the channel pore (24-27), and the beta  subunit (28-30), which modifies the voltage and calcium sensitivity of the pore-forming subunit (31). Both the human alpha  (hSlo) and beta  (hKv,Cabeta ) subunit genes encode several consensus cAMP-PK, although the site(s) associated with physiological regulation have not been determined. We examined beta -adrenergic receptor/maxi K coupling by coexpression of hSlo and hKv,Cabeta and the human beta 2-adrenergic receptor gene (hbeta 2AR) in Xenopus laevis oocytes using the two-electrode voltage clamp technique. We demonstrate that isoproterenol and forskolin increase maxi-K currents in voltage-clamped oocytes, that this action is mediated by PKA phosphorylation of the alpha  subunit, and that mutation of Ser-869 almost completely eliminates beta 2 receptor/channel coupling.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Expression of Maxi-K and beta 2 Receptor cRNAs in Xenopus Oocytes-- hSlo was obtained from Drs. Ligia Toro, Enrico Stefani, and Martin Walner (Department of Anesthesiology, UCLA, Los Angeles, CA) and from Dr. Lawrence Salkoff (Department of Genetics, Washington University, St. Louis, MO), and the Hbeta 2AR cDNA clone was obtained from Dr. Jeffery Benovic (Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA). We cloned hKV,Cabeta (32) by reverse transcription and polymerase chain reaction. Double-stranded cDNA was synthesized from human tracheal RNA (CLONTECH) using avian myeloblastosis virus-reverse transcriptase (Boehringer Mannheim); the cDNA was amplified with hKV,Cabeta -specific sense (5'-ATGGTGAAGCTGGTGATGGCC-3') and antisense (5'-CTACTTCTGGGCCGCCAGGAGGGA-3') primers, and the polymerase chain reaction fragment cloned in TA 2.1 cloning vector (Invitrogen) and sequenced.

Mutagenesis of the hSlo cDNA was carried out using the pAlter mutation kit (Promega). The full-length cDNA was subcloned in pAlter-1 vector at SmaI site after blunt ending with Klenow enzyme. The plasmid DNA was denatured with 2 M NaOH, 2 mM EDTA solution. The mutation primer, spanning from nucleotide 2596 to 2617 (5'-CGTCAACCATCCATCAGGAGGGA-3'), was annealed to the denatured DNA to mutate amino acid 869 from Ser to Ala. The annealed DNA was used to carry out site-specific mutagenesis using the manufacturer's protocol; mutated cDNA (hSlo(Delta S869A)) was confirmed by sequencing (33).

cRNA was prepared from the human maxi-K cDNAs (hSlo, hKV,Cabeta , hSlo(Delta S869A)) and hbeta 2AR cDNA using the mMessage mMachine kit (Ambion). The plasmid DNAs were linearized with appropriate restriction enzymes and the cRNAs were synthesized using T7 (hSlo, hKV,Cabeta ) and Sp6 (hbeta 2AR receptor) RNA polymerase enzymes (34). The integrity of the cRNAs was tested on ethidium bromide-stained agarose gels, and cRNA concentrations were estimated by spectrophotometric measurements.

Oocytes from X. laevis were prepared for injection as described previously (35). Channel and receptor cRNAs were mixed at final concentrations of 0.6-0.9 µg/µl and 0.35-0.45 µg/µl, respectively; the final concentration of hKV,Cabeta cRNA was adjusted to achieve a 1:2 molar ratio to hSlo, so that all expressed channel alpha  subunits would likely interact with beta  subunits (32). Approximately 50 nl of these solutions were injected per oocyte, and oocytes were then incubated for 3-6 days in ND96 (96 mM NaCl, 2.0 mM KCl, 1.8 mM CaCl2, 1.0 mM MgCl2, 5.0 mM HEPES, pH 7.5) with sodium pyruvate (5.0 mM), penicillin (100 units/ml), and streptomycin (100 µg/ml) at 18 °C.

Electrophysiology-- Two-electrode voltage clamp measurements were made at room temperature in ND96, using pipettes of 0.3-1.0 megohms resistance filled with 3 M KCl. Currents were amplified (OC-725C, Warner Instrument, Hamden, CT), filtered at 200 Hz (-3 dB; 8-pole Bessel filter, model 902, Frequency Devices), digitized at 1 kHz (Digidata, Axon Instruments), monitored (pClamp, Axon Instruments), and simultaneously stored on disk. Maxi-K currents were monitored by holding the membrane potential constant at -60 mV and imposing a 500-ms test pulse to 60 mV, every 20 s. Following voltage clamp initiation, currents were monitored for a 5-min equilibration period; oocytes in which currents spontaneously varied in amplitude over this period were discarded. All currents are shown after leak subtraction. Results are expressed as means ± S.E. Statistical significance was determined using Student's t test for paired observations.

Chemicals-- Isoproterenol and forskolin were obtained from Sigma. Iberiotoxin was purchased from Peptide Institute (Osaka, Japan), and the PKA regulatory subunit was obtained from Promega (Madison, WI). 50 nl (3.125 units) of PKA regulatory subunit peptide was injected for kinase inhibition. The peptide PKG inhibitor used was the 7-residue peptide corresponding to histone H2B (residues 29-35), obtained from Calbiochem.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Reconstitution of beta 2-Adrenergic Stimulation of Maxi-K Channels-- Xenopus oocytes expressing the human beta 2-adrenergic receptor (beta 2AR) and either the pore-forming (alpha ) subunit, or the pore-forming and regulatory (alpha  + beta ) subunits of the human maxi-K channel were examined in two-electrode voltage-clamp experiments. Functional expression of channel proteins was determined by activation of iberiotoxin sensitive outward currents. As reported previously (30, 31), average currents recorded from oocytes injected with both channel subunit cRNAs were larger at all voltages than those recorded from oocytes injected with hSlo alone (3225.8 ± 256.9 nA (n = 25) versus 2671.9 ± 365.5 nA (n = 14) at 60 mV). As shown in Fig. 1, application of the beta -adrenergic receptor agonist isoproterenol (ISO) to oocytes injected with hSlo, hKV,Cabeta , and hbeta 2AR cRNAs resulted in a rapid stimulation of maxi-K current monitored with a clamp step to 60 mV. The current was maximally stimulated 78 ± 11 s after ISO addition (n = 17; current examined at 20-s intervals), and fell to prestimulation levels upon removal of the agonist. Iberiotoxin, a highly specific peptidyl inhibitor of maxi-K channels (36), blocked almost all of the voltage-dependent current, and isoproterenol failed to activate a current in the presence of the maxi-K antagonist (Fig. 1A). As shown in Table I, the mean current stimulation by 10 µM ISO was 33.3 ± 5.1% (60 mV), whereas ISO had no effect on oocytes injected with cRNA encoding only the channel subunits (without hbeta 2AR), or on oocytes injected with only hbeta 2AR (without maxi-K channel genes). Qualitatively similar results were observed in oocytes injected with only hSlo and hbeta 2AR cRNAs (Fig. 1B), i.e. ISO stimulated alpha  subunit maxi-K currents to a degree similar to that for alpha /beta currents (25.8 ± 5.3 versus 33.3 ± 5.1%; Table I). In both cases, ISO stimulation was not associated with an alteration in current activation or decay kinetics; rather, stimulated alpha /beta or alpha  maxi-K currents were scaled increases of control currents. Current stimulation was observed over the entire voltage range examined, resulting in a marked shift in the conductance/voltage relationship toward more negative potentials (Fig. 1C).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   Stimulatory coupling between heterologously expressed beta 2 receptors and maxi-K channels. A, ISO (10 µM) stimulates currents recorded from a voltage-clamped Xenopus oocyte coexpressing human beta 2-adrenergic receptor and maxi-K channel (alpha  and beta  subunits) genes. Data points show peak current at voltage clamp steps from -60 to +60 mV at 20-s intervals. ISO application resulted in an increase in the current amplitude within 1 min. Outward current was almost completely abolished by 100 nM iberiotoxin (IBTX), after which no current stimulation was observed. B, representative traces before and after stimulation with ISO (10 µM). Traces at left were obtained in an experiment in which both channel subunits were expressed, whereas traces at right were from the channel alpha  subunit alone. ISO resulted in a scaled increase in the maxi-K current. Currents were elicited by a 500-ms step depolarization from -60 mV to +60 mV; scale bars are 1 µA and 100 ms. C, ISO stimulation resulted in an increase in the maxi-K conductance at all potentials. Experiment shows the mean conductance from eight experiments in which a current/voltage analysis was performed. Solid lines are Boltzmann fits to the data; error bars indicate standard error.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of isoproterenol (ISO) and forskolin on currents from oocytes expressing various maxi-K channel subunits and beta 2-receptor combinations
Data were obtained by averaging five currents at peak stimulation and calculating the percent stimulation above the average of five currents immediately before drug application. Diagrams at left refer to injected cRNAs; beta 2 refers to the human beta 2 adrenergic receptor, alpha  to the human maxi-K pore-forming subunit, and beta  to the human maxi-K regulatory subunit. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Mechanism of beta 2AR/Maxi-K Channel Coupling-- To determine whether beta 2AR/maxi-K channel coupling occurs via stimulation of adenylyl cyclase and activation of cAMP-PK, we first examined the stimulation of maxi-K currents by forskolin in oocytes expressing alpha /beta or alpha  channel subunits. As shown in Fig. 2A, forskolin (10 µM) stimulated maxi-K currents to a degree that was similar to that observed with ISO (34.9 ± 7.8% stimulation at 60 mV), although the time to peak was substantially slower than observed following exposure to ISO (466 ± 35 s; n = 13). As with ISO, forskolin application did not result in an alteration of current kinetics, but in a scaled increase in the current at all voltages (Fig. 2B), and stimulated both alpha /beta and alpha  maxi-K currents to a similar degree (Table I). Taken together with results obtained with ISO, these data indicate that the regulatory target associated with beta 2AR receptor stimulation is the channel alpha  subunit.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Stimulation of heterologously expressed maxi-K channels by forskolin. A, application of forskolin (10 µM) stimulated heterologously expressed maxi-K currents (alpha  and beta  subunits), as shown by the plot of peak current. The maximum stimulatory effect was observed after 10 min and was poorly reversible. No current augmentation was observed in the presence of iberiotoxin (100 nM). Currents were obtained by voltage clamp steps from -60 to +60 mV at 20 s. B, current traces from similar experiments show current augmentation before and after peak forskolin effect for expression of both channel subunits or the alpha  subunit alone. As with ISO, stimulated currents were scaled increases in the basal current. Currents shown were from 500 ms clamp steps to +60 mV; scale bars indicate 1 µA and 100 ms.

It has been suggested that beta 2AR-mediated stimulation of maxi-K currents is associated with stimulation of cGMP-dependent protein kinase (cGMP-PK) rather than cAMP-PK (23), and that stimulation may occur via a direct interaction between G protein subunits and the channels (12, 13). We directly examined the role of cAMP-PK in beta 2AR/maxi-K coupling by intracellular injection cAMP-PK and cGMP-PK regulatory peptides. As shown in Fig. 3, ISO stimulation was quite similar before and after sham injection of oocytes, whereas injection of the PKA regulatory subunit markedly reduced ISO stimulation. In three of four experiments, injection of the regulatory subunit inhibited the previous ISO stimulation by 57% (28.2 ± 9.6 versus 12.2 ± 2.8% stimulation before and after injection of peptide), clearly indicating a role for cAMP-PK in receptor/channel coupling. Conversely, ISO stimulated maxi-K currents in oocytes injected with cGMP-PK inhibitory peptide (final concentration 80 µM) by 23.9 ± 6.2% (n = 6, data not shown). This level of stimulation was less than observed with ISO alone; however, the degree of current stimulation was consistent with the Ki of the peptide for cAMP-PK (predicted to inhibit the kinase by about 13%). To determine whether the mode of receptor/channel coupling was sensitive to the amount of expressed receptor, we performed experiments in the amount of injected beta 2 receptor cRNA was reduced 10-fold (2.5 ng); however, no current stimulation was observed under these conditions (-1.6 ± 0.4%, n = 6; data not shown).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of cAMP-PK markedly decreases beta 2AR/maxi-K stimulatory coupling. A, in control stimulatory experiments, ISO (10 µM) application repeatedly augmented maxi-K currents. B, following initial ISO stimulation, oocyte was injected with 3.125 units of cAMP-PK regulatory subunit. Subsequent applications of ISO were markedly less effective in stimulation maxi-K currents. All currents were obtained by step depolarizations from -60 to +60 mV at 20-s intervals.

The mammalian homologues of dSlo do not share the optimal cAMP-PK phosphorylation site of dSlo (24, 37), but share a conserved, less cAMP-PK-specific phosphorylation site at approximately the same position (e.g. 866-869, GenBank accession no. U11058), as well as several other potential phosphorylation sites. To determine the relevant phosphorylation site associated with physiological beta 2AR stimulation, we used site-directed mutagenesis to replace serine 869 with alanine (hSlo(Delta S869A)), and coexpressed the mutant channel subunit with the beta  subunit and the beta 2AR. As shown in Fig. 4, hSlo(Delta S869A)/beta currents were almost completely insensitive to modulation by ISO; ISO increased the current amplitude by 5.5 ± 1.3% (n = 9), whereas exposure to forskolin still produced a significant increase in current magnitude (16.0 ± 3.9%; n = 9), although substantially less than in the wild type channels (Table I). The amplitude and kinetics of hSlo(Delta S869A)/beta currents were not different from hSlo(wt)/beta currents (data not shown). These data indicate that cAMP-dependent phosphorylation occurs at Ser-869.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4.   Mutation of serine 869 abolishes beta 2AR/maxi-K stimulatory coupling. ISO application to an oocyte injected with wild type beta 2AR and maxi-K beta  subunit genes, and a mutant maxi-K alpha  subunit gene (Delta S869A). Whereas ISO (10 µM) failed to stimulate the current, forskolin (10 µM) produced a modest increase in current magnitude with kinetics similar to that observed in wild type experiments. The experimental protocol was the same as described for Fig. 1.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The present study demonstrates the reconstitution of beta 2-adrenergic receptor stimulatory coupling to maxi-K channels by heterologous expression of receptor and channel RNAs in X. laevis oocytes. Isoproterenol and forskolin increased maxi-K currents in oocytes expressing either the pore-forming alpha  subunit alone, or co-expressing the alpha  and regulatory beta  subunits (Figs. 1 and 2, Table I). The stimulated currents were not endogenous oocyte currents since there was no augmentation of outward current in oocytes expressing beta 2 receptors but not maxi-K channels, and since forskolin, but not ISO, stimulated currents in oocytes expressing maxi-K channels, but not beta 2 receptors (Table I). Moreover, virtually all of the outward current was inhibited by iberiotoxin (Figs. 1 and 2), a selective peptidyl inhibitor of maxi-K channels (36). Since heterologous expression avoids complications associated with expression of multiple receptor or channel subtypes in target tissues, the present results clearly establish stimulatory coupling between human beta 2 receptors and maxi-K channels. Further, since stimulation was achieved with expression of only the beta 2 receptor and the alpha subunit and the degree of stimulation was similar with or without the regulatory beta  subunit (Table I), these studies localize the modulatory site to the channel alpha  subunit. It should be noted that the degree of stimulation observed (30-35%) is somewhat less than reported in mammalian cells. In smooth muscle cells, current stimulation varies from approximately 50% to 100%, and is somewhat dependent on the step voltage and [Ca2+]i (7, 38, 39).

Considerable controversy exists with respect to the mechanism of stimulatory coupling to maxi-K channels. Stimulatory mechanisms that have been proposed include cAMP-dependent phosphorylation (5, 6, 11, 15, 16), cGMP-dependent phosphorylation (17, 18, 20, 21, 40), cGMP-dependent dephosphorylation (19, 22, 23), by G protein subunits (12, 13), and direct stimulation by NO (41). We used the heterologous expression system and site-directed mutagenesis to identify the mechanism of beta  adrenergic stimulatory coupling to maxi-K channels and to identify the relevant channel modulatory site. Our data clearly implicate cAMP-PK in beta 2 receptor/channel stimulatory coupling since injection of the regulatory subunit of cAMP-PK disrupts beta 2 receptor/maxi-K channel stimulatory coupling (Fig. 3). In addition to disrupting stimulatory coupling, injection of oocytes with the cAMP-PK regulatory subunit also consistently reduced the amplitude of the basal current before application of isoproterenol (Fig. 3B), suggesting that phosphorylation by cAMP-PK regulates maxi-K channel activity under resting conditions. Conversely, a semi-selective (6-fold) cGMP-PK inhibitory peptide only slightly reduced ISO current stimulation, consistent with the predicted inhibition of cAMP-PK. Further evidence suggesting functional modulation of maxi-K channels by cAMP-PK was the finding that heterologously expressed maxi-K channels are stimulated by forskolin, and that this stimulation occurs with or without expression of the beta 2 receptor (Fig. 2, Table I).

dSlo, the Drosophila maxi-K channel gene, contains a single optimal consensus sequence for PKA phosphorylation in the C-terminal region of the protein (RRGS at 959-962; Ref. 24), and mutations at this site were later found to prevent channel activation by exogenous PKA in inside-out patches (42). The mammalian homologues of dSlo contain a less cAMP-PK -specific phosphorylation site at approximately the same position (RQPS at 866-869, e.g. GenBank accession no. U11058), which is conserved in mammalian genes, and which occupies a similar position upstream of a highly conserved region, aspartate-rich region that is a likely calcium-binding site (43). However, as many as 10 other potential cAMP-PK consensus phosphorylation sites exist throughout the coding region of the alpha  subunit (37). To ascertain the physiologically relevant phosphorylation site, we mutated serine 869 to alanine, and coexpressed the mutant alpha  subunit with the wild type beta  subunit and the beta 2 receptor. This single mutation markedly reduced, but did not abolish, beta 2 receptor stimulation of the current (from 33.3 ± 5.1% to 5.5 ± 1.3%, Table I), strongly implicating serine 869 in receptor/effector coupling. The low degree of current stimulation consistently observed in the mutant may relate to a slight role for additional cAMP phosphorylation sites, coupling through other kinases, or direct G protein interactions. Moreover, forskolin stimulation was only decreased by about half in mutant channels, suggesting that additional sites of channel modulation exist. It is possible that the dominant mechanism of stimulatory coupling observed in our experiments relates to factors unique to the Xenopus oocyte, such as cell size or endogenous G proteins, and that other regulatory mechanisms may be more prominent in mammalian cells. However, our results are consistent with the major mechanism of beta 2 receptor/maxi-K channel stimulatory coupling occurring by cAMP-PK phosphorylation of serine 869.

Finally, the stimulatory effect of both the beta 2 receptor agonist ISO and forskolin was an increase in current amplitude at all voltages, without a change in current kinetics, similar to the modulatory action of beta 2 receptor stimulation on cardiac sodium channel alpha  subunits heterologously expressed in Xenopus oocytes (44). In that study, mutation of all consensus cAMP-PK sites on the sodium channel failed to remove channel stimulation, leading to the suggestion that modulation might occur by phosphorylation of an unrelated protein resulting in a redistribution of channels to the plasma membrane (44). ISO stimulation of sodium currents was quite slow (approximately 10 min to maximum stimulation), which could be consistent with a redistribution of membranes within the oocyte. In the present study, however, stimulatory coupling occurred quite rapidly (approximately 1 min to maximum), which would be consistent with a direct effect on channel gating.

In summary, we have used a heterologous expression system to demonstrated beta 2-adrenergic receptor/maxi-K channel stimulatory coupling. Coupling involves a cAMP-PK-dependent phosphorylation of the channel alpha  subunit; mutation of one consensus cAMP-PK phosphorylation site (serine 869) almost eliminates beta 2-adrenergic modulation of the maxi-K current. These findings do not rule out other modulatory mechanisms, but do confine the physiologically relevant molecular mechanisms associated with beta 2 receptor/maxi-K channel coupling.

    ACKNOWLEDGEMENTS

We thank Laura Lynch for technical assistance; Drs. L. Toro, E. Stefani, M. Wallner, L. Salkoff, and J. Benovic for supplying cDNAs; and Dr. P. Drain for assistance with oocyte collection.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce St., Philadelphia, PA 19104-6046. Tel.: 215-898-2839; Fax: 215-573-6810; E-mail: mik{at}phila.vet.upenn.edu.

1 The abbreviations used are: maxi-K, large conductance, calcium-activated potassium; cAMP-PK, cAMP-dependent protein kinase; cGMP-PK, cGMP-dependent protein kinase; PKA, cAMP-dependent protein kinase; beta 2AR, beta 2-adrenergic receptor; ISO, isoproterenol.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Levitan, I. B. (1994) Annu. Rev. Physiol. 56, 193-212[CrossRef][Medline] [Order article via Infotrieve]
  2. Wickman, K., and Clapham, D. E. (1995) Physiol. Rev. 75, 865-885[Abstract/Free Full Text]
  3. Bulbring, E., and Tomita, T. (1987) Pharmacol. Rev. 39, 49-96[Medline] [Order article via Infotrieve]
  4. Sadoshima, J., Akaike, N., Kanaide, H., and Nakamura, M. (1988) Am. J. Physiol. 255, H754-H759[Abstract/Free Full Text]
  5. Kume, H., Takai, A., Tokuno, H., and Tomita, T. (1989) Nature 341, 152-154[CrossRef][Medline] [Order article via Infotrieve]
  6. Kume, H., Hall, I. P., Washabau, R. J., Takagi, K., and Kotlikoff, M. I. (1994) J. Clin. Invest. 93, 371-379[Medline] [Order article via Infotrieve]
  7. Song, Y., and Simard, J. M. (1995) Pflugers Arch. Eur. J. Physiol. 430, 984-993[Medline] [Order article via Infotrieve]
  8. Jones, T. R., Charette, L., Garcia, M. L., and Kaczorowski, G. J. (1990) J. Pharmacol. Exp. Ther. 255, 697-706[Abstract]
  9. Jones, T. R., Charette, L., Garcia, M. L., and Kaczorowski, G. J. (1993) J. Appl. Physiol. 74, 1879-1884[Abstract]
  10. Miura, M., Belvisi, M. G., Stretton, D., Yacoub, M. H., and Barnes, P. J. (1992) Am. Rev. Respir. Dis. 146, 132-136[Medline] [Order article via Infotrieve]
  11. Carl, A., Kenyon, J. L., Uemura, D., Fusetani, N., and Sanders, K. M. (1991) Am. J. Physiol. 261, C387-C392[Abstract/Free Full Text]
  12. Kume, H., Graziano, M. P., and Kotlikoff, M. I. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11051-11055[Abstract]
  13. Scornik, F. S., Codina, J., Birnbaumer, L., and Toro, L. (1993) Am. J. Physiol. 265, H1460-H1465[Abstract/Free Full Text]
  14. Lee, M. Y., Bang, H. W., Lim, I. J., Uhm, D. Y., and Rhee, S. D. (1994) Pflugers Arch. Eur. J. Physiol. 429, 150-152[Medline] [Order article via Infotrieve]
  15. Savaria, D., Lanoue, C., Cadieux, A., and Rousseau, E. (1992) Am. J. Physiol. 262, L327-L336[Abstract/Free Full Text]
  16. Meera, P., Anwer, K., Monga, M., Oberti, C., Stefani, E., Toro, L., and Sanborn, B. M. (1995) Am. J. Physiol. 269, C312-C317[Abstract/Free Full Text]
  17. Taniguchi, J., Furukawa, K. I., and Shigekawa, M. (1993) Pflugers Arch. Eur. J. Physiol. 423, 167-172[Medline] [Order article via Infotrieve]
  18. Robertson, B. E., Schubert, R., Hescheler, J., and Nelson, M. T. (1993) Am. J. Physiol. 265, C299-C303[Abstract/Free Full Text]
  19. White, R. E., Lee, A. B., Shcherbatko, A. D., Lincoln, T. M., Schonbrunn, A., and Armstrong, D. L. (1993) Nature 362, 263-266
  20. White, R. E., Darkow, D. J., and Lang, J. L. (1995) Circ. Res. 77, 936-942[Abstract/Free Full Text]
  21. George, M. J., and Shibata, E. F. (1995) J. Invest. Med. 43, 451-458[Medline] [Order article via Infotrieve]
  22. White, R. E., Schonbrunn, A., and Armstrong, D. L. (1991) Nature 351, 570-573[CrossRef][Medline] [Order article via Infotrieve]
  23. Zhou, X. B., Ruth, P., Schlossmann, J., Hofmann, F., and Korth, M. (1996) J. Biol. Chem. 271, 19760-19767[Abstract/Free Full Text]
  24. Atkinson, N. S., Robertson, G. A., and Ganetzky, B. (1991) Science 253, 551-553[Medline] [Order article via Infotrieve]
  25. Adelman, J. P., Shen, K.-Z., Kavanaugh, M. P., Warren, R. A., Wu, Y.-N., Lagrutta, A., Bond, C. T., and North, R. A. (1992) Neuron 9, 209-216[Medline] [Order article via Infotrieve]
  26. Butler, A., Tsunoda, S., McCobb, D. P., Wei, A., and Salkoff, L. (1993) Science 261, 221-224[Medline] [Order article via Infotrieve]
  27. Pallanck, L., and Ganetzky, B. (1994) Hum. Mol. Genet. 3, 1239-1243[Abstract]
  28. Garcia-Calvo, M., Knaus, H.-G., McManus, O. B., Giangiacomo, K. M., Kaczorowski, G. J., and Garcia, M. L. (1994) J. Biol. Chem. 269, 676-682[Abstract/Free Full Text]
  29. Knaus, H. G., Folander, K., Garcia-Calvo, M., Garcia, M. L., Kaczorowski, G. J., Smith, M., and Swanson, R. (1994) J. Biol. Chem. 269, 17274-17278[Abstract/Free Full Text]
  30. Tseng-Crank, J., Godinot, N., Johansen, T. E., Ahring, P. K., Strobaek, D., Mertz, R., Foster, C. D., Olesen, S.-P., and Reinhart, P. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9200-9205[Abstract/Free Full Text]
  31. McManus, O. B., Helms, L. M. H., Pallanck, L., Ganetzky, B., Swanson, R., and Leonard, R. J. (1995) Neuron 14, 645-650[Medline] [Order article via Infotrieve]
  32. Meera, P., Wallner, M., Jiang, Z., and Toro, L. (1996) FEBS Lett. 382, 84-88[CrossRef][Medline] [Order article via Infotrieve]
  33. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467[Abstract]
  34. Melton, D. A. (1987) Methods Enzymol. 152, 288-296[Medline] [Order article via Infotrieve]
  35. Goldin, A. L. (1992) Methods Enzymol. 207, 266-279[Medline] [Order article via Infotrieve]
  36. Galvez, A., Gimenez-Gallego, G., Reuben, J. P., Roy-Contancin, L., Geigenbaum, P., Kaczorowski, G. J., and Garcia, M. L. (1990) J. Biol. Chem. 265, 11083-11090[Abstract/Free Full Text]
  37. Kennelly, P. J., and Krebs, E. G. (1997) J. Biol. Chem. 266, 15555-15558[Free Full Text]
  38. Anwer, K., Toro, L., Oberti, C., Stefani, E., and Sanborn, B. M. (1992) Am. J. Physiol. 263, C1049-C1056[Abstract/Free Full Text]
  39. Fan, S.-F., Wang, S., and Kao, C. Y. (1993) J. Gen. Physiol. 102, 257-275[Abstract]
  40. Carrier, G. O., Fuchs, L. C., Winecoff, A. P., Giulumian, A. D., and White, R. E. (1997) Am. J. Physiol. 273, H76-H84[Abstract/Free Full Text]
  41. Bolotina, V. M., Najibi, S., Palacino, J. J., Pagano, P. J., and Cohen, R. A. (1994) Nature 368, 850-853[CrossRef][Medline] [Order article via Infotrieve]
  42. Chung, S. K., Reinhart, P. H., Martin, B. L., Brautigan, D., and Levitan, I. B. (1991) Science 253, 560-562[Medline] [Order article via Infotrieve]
  43. Schreiber, M., and Salkoff, L. (1997) Biophys. J. 73, 1355-1363[Abstract]
  44. Schreibmayer, W., Frohnwieser, B., Dascal, N., Platzer, D., Spreitzer, B., Zechner, R., Kallen, R. G., and Lester, H. A. (1994) Receptors Channels 2, 339-350[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.